Please Wait...

Analytical Performance Characteristics of a Novel Immunoassay for Quantification of Neurogranin Truncp75 in Human Cerebrospinal Fluid

E.Chassaing, M.Bodnar-Wachtel, T.Schubert, H.Vanderstichele, E.Stoops, and P.Vergnaud

OBJECTIVES

Despite the fact that the core CSF biomarkers (tau, amyloid) reflect on-going pathology in the brains of subjects with Alzheimer’s Disease (AD), new biomarkers are needed to monitor other hallmarks, such as synaptic degeneration. This study documents the analytical performance characteristics of a novel ELISA, targeting P75 truncated Neurogranin, which has been shown to be the most abundant Neurogranin isoform in CSF.

METHODS

After having performed familiarization runs and adaptation of the test procedures to the needs of a service provider, the assay was challenged internally for its analytical performance characteristics (eg, precision, parallelism, spike-recovery, working range, sample stability) by using commercially available CSF samples (n=32).

RESULTS

The new assay format specifically quantifies Neurogranin truncated at position 75. Full-length Neurogranin is not detected. Neurogranin is quantified in the absence of matrix interference (parallelism 101% ± 8%; dilution range: neat – 1/16). Spike/recovery testing revealed good recovery rates (100% ± 8%). The precision resulted in intra- and inter-assay variability (%CV) below 7% and 13%, respectively. The working range is confirmed between 50 pg/mL (Lower Limit of Quantitation) to 1300 pg/mL (Upper Limit of Quantitation). CSF stability at +4°C is acceptable, but storage at room temperature should not exceed 6 hours; consecutive freezing/thawing of CSF up to 4 cycles did not affect Neurogranin concentrations. The assay format is also applicable to EDTA-plasma samples.

CONCLUSIONS

The newly developed Neurogranin TruncP75 colorimetric ELISA assay meets all internal acceptance criteria for clinical trial sample testing and represents an additional tool for patient management.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Clinical #datamanagement is essential to ensure high-quality data in #clinicaltrials, but the components are comple… https://t.co/klK81O6YA2
Bioclinica (18 hours ago)
Congratulations to Jeff Heilbraun, M.S., VP, Medical & Scientific Affairs, for his latest article on cardiovascular… https://t.co/JSuEaeQOYh
Bioclinica (5 days ago)
Changes are a fact of life - and of #clinicaltrial design. But planning and budgeting for your trial don’t have to… https://t.co/wsfMPAwLxR
Bioclinica (3 weeks ago)
Don't compromise with manual systems and spreadsheets. As an entry-level system with phased implementation, Bioclin… https://t.co/dYDJO4Qh7S
Bioclinica (3 weeks ago)
Our webinar on Neuroimaging in Parkinson’s Disease is tomorrow at 10:30 a.m. EDT. Register at:… https://t.co/4j0FGeXG0B
Bioclinica (3 weeks ago)
Today is World Ovarian Cancer Day. Ovarian cancer has the lowest survival rate of all female cancers. #Bioclinica p… https://t.co/1nMGahTMaz
Bioclinica (4 weeks ago)